Skip to main content

Rheumatoid Arthritis

Anti-inflammatory Diet Control of Rheumatoid Arthritis

Apr 09, 2021

The TOMORROW study assessed the relationship between diet and disease activity in rheumatoid arthritis (RA) patients and has shown that RA patients are more likely to have higher inflammatory diets, but that a change to an anti-inflammatory diet resulted in lower disease activity scores.

Read Article

Overview of New VEXAS Syndrome

Apr 08, 2021

Medscape offers up an informative overview of the newly described syndrome called VEXAS discovered by researchers at the National Institutes of Health. These patients were previously misdiagnosed with Sweets syndrome, relapsing polychondritis, myelodysplastic syndrome, MGUS, or polyarteritis

Read Article

Can Targeting RANKL in RA Heal Erosions?

MedPage Today
Apr 07, 2021

Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported.

Read Article

Implementing Smoking Cessation Programs

Apr 07, 2021

Rheumatologists are keen to the effects of smoking (increased arthritis risk, worse outcomes, blunted DMARD responses, added cardiopulmonary risks), but often do not have the resources or plan to encourage or implement smoking cessation from the rheumatology clinic. A new study details the

Read Article

Rheumatology Care Derailed by COVID-19

Apr 06, 2021

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.



Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by

Read Article

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Apr 02, 2021

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Mar 31, 2021

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.



Data derived from the retrospective

Read Article
From Dr. Petryna ( @DrPetryna ) on Pneumonia & RA #RNL2021 : -PNA most common hospital inf in RA and main cause of hosp mortality -seropositivity assoc w/increase risk of PNA -COPD+RA bad combo: increase PNA & mortality #RheumNow https://t.co/IgXfJTMrcn
Dr. John Cush @RheumNow( View Tweet )
Mar 31, 2021
Metanalysis of 32 studies shows most forms of arthritis assoc w/ incr risk of CVA (ischemic stroke: RR=1.53 or hemorrhagic stroke: RR=1.45), esp for RA (RR=1.38), AS (RR=1.49), PsA (RR=1.33), gout (RR=1.4) --risk higher with age <45 years (RR=1.46) https://t.co/YDiebrqtbi

Dr. John Cush @RheumNow( View Tweet )

Mar 31, 2021
From @KDAO2011 for #RNL2021 Is it better to taper the steroids or leave it? SEMIRA study. Tapering off low dose steroids cause more flares and more treatment side effects. Dr. Buttgereit says keep your low dose steroids (prednisone 5 mg/day or less) https://t.co/FpQnxUKWwF

Dr. John Cush @RheumNow( View Tweet )

Mar 30, 2021
A prevention trial shows atorvastatin failed to prevent RA onset - 62 pts with preclinical RA (arthralgia, +CCP/RF) randomized to PBO or statin. After 14 mos, arthritis developed in 29% with atorvastatin and 19% with placebo. https://t.co/HikuDkwNu7 https://t.co/QyGy81lgcq
Dr. John Cush @RheumNow( View Tweet )
Mar 30, 2021
Liver Management in RA - #RNL2021 Highlight by @DrPetryna While RA is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the mgmt of many RA patients. https://t.co/OeuloDIXMF

Dr. John Cush @RheumNow( View Tweet )

Mar 27, 2021
#RNL2021 Highlights: Future Therapeutics for Rheumatoid Arthritis and Lessons Learned https://t.co/NxLyHeI2f4 https://t.co/df7lPEia0D
Dr. John Cush @RheumNow( View Tweet )
Mar 26, 2021
Claims data analysis (MarketScan, Medicare, Optum) of 87,653 RA patients starting either TNF inhibitor or tofacitinib shows venous thromboembolism (VTE) is rare (<1 per 100) RA Rx with either. VTE risk was same for Tofa and TNFi (HR of 1.13 [0.77-1.65]) https://t.co/UoMQRp12vo

Dr. John Cush @RheumNow( View Tweet )

Mar 25, 2021
Dr. Fleischmann vs. Dr. Matsumoto: get rid of MTX vs. get rid of biologic in RA remission. Both argue on sustained remission, risk for anti-drug antibodies, longterm safety. Dr. Buch’s perfect answer… “it depends on patient’s preference, cost.” #RNL2021 https://t.co/FBf2uoDx0B
Mar 25, 2021

Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights

Mar 24, 2021

In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning. In the Day 1 learning pods, the audience was given a tour of the new drugs in development for RA. Several noteworthy ones were

Read Article
Adding RTX to leflunomide works but may at ACR50 level. 140 RA pts on LEF given RTX or PBO w/ ongoing LEF. Wk 16, RTX+LEF ACR50=32% (vs PBO 15%; P=0.02), but not wk 24 (27 vs 15%), yet ACR20 was signif. RTX had more SAEs (20 vs 2%) https://t.co/t6Z9m7P2Ur

Dr. John Cush @RheumNow( View Tweet )

Mar 23, 2021
News Feature: Liver Management in Rheumatoid Arthritis - #RNL2021 Highlight by Dr. Olga Petryna ( @DrPetryna ) https://t.co/OeuloE0yEd https://t.co/qYd1K0dADu
Dr. John Cush @RheumNow( View Tweet )
Mar 23, 2021
Dr. Buch discusses the differences between difficult to treat vs refractory RA in #RNL2021. @RheumNow https://t.co/TqrHcBt0la
Dr. Rachel Tate @uptoTate( View Tweet )
Mar 23, 2021
News Feature: Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease https://t.co/2P0tdxvZD2 https://t.co/7gfE1CPSEx
Dr. John Cush @RheumNow( View Tweet )
Mar 22, 2021

Liver Management in Rheumatoid Arthritis - RNL2021 Highlight

Mar 22, 2021

While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr. Stanley Cohen detailed many issues

Read Article
Early RA pts given steroids (GC) do Not have short or long term benefits from GCs. 180 ERA pts given compared to 294 who did not. 5 yr F/U showed no differences in DAS28-CRP, HAQ or pain between groups. Steroids were used more in seronegative RA. https://t.co/CDUKDgsLRa

Dr. John Cush @RheumNow( View Tweet )

Mar 22, 2021
Using both glucocorticoids & PPI leads to additive risk of osteoporotic fractures - UK database studiedd 12351 RA pts - 1411 w/ OP Fx. Concomitant GCs + PPIs assoc w/ 1.6-fold risk of OP Fx (adj HR: 1.60) vs nonuse; more than 1.2-fold risk w/ either alone https://t.co/vvA6P5LEgs

Dr. John Cush @RheumNow( View Tweet )

Mar 22, 2021
Mavrilimumab (anti-GM-CSF) metanalysis shows gret benefit in #RA - 1145 pts, 3 trials shows significant 12 week responses by: 1) DAS28-CRP remission (RR = 3.31); 2) ACR20 (RR = 2.38); 3) ACR50 (RR = 2.93) & 4) ACR70 (RR = 4.9). Where is it? https://t.co/9L5PFEB1DI

Dr. John Cush @RheumNow( View Tweet )

Mar 21, 2021
Leading the Rheumatoid Arthritis pod with discussions on pneumonia and RA and interstitial lung disease in RA. #RNL2021 https://t.co/psxMTHsOva
Dr. John Cush @RheumNow( View Tweet )
Mar 20, 2021
×